CYP2C19 and gastroesophageal reflux disease: Cases of abnormal esophageal reflux despite PPI therapy have been reported due to a lack of PPI efficacy.(14) The cause is thought to be due to differences the phenotype of CYP2C19, the metabolizing enzyme for PPIs.